IL6 and colitis: The administration of the selective A2BAR antagonist 1-cyclopropyl-3-propyl-8-(6-(N-nicotinoyl-N-ethylamino)-3-pyridyl)xanthine (ATL-801) to a mouse model of colitis markedly decreases IL-6 secretion and neutrophil infiltration, and reduces the extent of mucosal damage, thus ameliorating the disease course [94].